Real-World Findings Reinforce Encelto’s Role in MacTel Treatment - Takeaways - MDSpire

Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

  • By

  • Jim Gallagher, senior managing editor

  • June 1, 2026

  • 4 min

Share

  • 1

    Encelto, an encapsulated cell therapy, shows sustained effects in treating macular telangiectasia type 2 (MacTel) based on early real-world experience.

  • 2

    Clinical trials indicated a 36% reduction in photoreceptor loss over 2 years, with functional benefits including a 68% reduction in monocular reading speed loss.

  • 3

    Surgical techniques for Encelto implantation have evolved to minimize device-related complications, including refined suture mechanics and knot techniques.

  • 4

    Safety findings in real-world use align with clinical trials, with about 20% of patients experiencing mild delayed dark adaptation and miosis.

  • 5

    Patient selection is crucial, with younger patients and those with less ellipsoid zone loss identified as stronger responders to Encelto treatment.

Original Source(s)

Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

  • by Jim Gallagher, senior managing editor

  • June 1, 2026

Related Content

Distinctive vascular changes in the retina and choroid linked to retrograde flow in the ophthalmic artery due to chronic total occlusion of the carotid artery

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.